Research programme: glutathione peroxidase mimetics - Synvista Therapeutics

Drug Profile

Research programme: glutathione peroxidase mimetics - Synvista Therapeutics

Latest Information Update: 07 Apr 2009

Price : $50

At a glance

  • Originator Synvista Therapeutics
  • Class
  • Mechanism of Action Glutathione peroxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Autoimmune disorders; Cardiovascular disorders; Liver disorders

Most Recent Events

  • 17 Sep 2008 Preclinical trials in Atherosclerosis in USA (unspecified route)
  • 24 Jul 2007 Alteon is now called Synvista Therapeutics
  • 12 May 2006 Preclinical trials in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top